Current Report · Items 2.02, 9.01 · 8-K

Repligen Corporation

RGENNASDAQEQUITYCurrent

Results of Operations and Financial Condition

Filed Jul 28, 2026Accepted Jul 28, 2026, 7:13 AM EDTCIK 730272Accession 0001193125-26-318853

Press release in this filing

Repligen Reports Second Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance →

Company context

Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve, primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, Germany, Ireland, the Netherlands and Sweden. For more information about the company see our website at www.repligen.com, and follow us on LinkedIn.

Current securities

RGENNASDAQ · EQUITY · Current

Recent company filings

Registered securities in this filing

REPLIGEN CORP · 8-K · Filed 2026-07-28

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock, par value $0.01 per share

Symbol: RGEN
Exchange: NASDAQ
Classification: COMMON
Status: Current

Filing context

Context: C_5b8f5213-3a05-442b-a59a-6a76573c938a

Dimensions: Not supplied

Accession 000119312526318853 · 1 registered-security cover member

Read the exact SEC filing ↗

Disclosure sections

Items 2.02, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 2.02Item 2.02 - Results of Operations

Item 2.02 Results of Operations and Financial Condition. On July 28, 2026, Repligen Corporation announced its financial results for the second quarter ended June 30, 2026. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Form 8-K and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Filed exhibits (1)

EX-99.1 (by filename) rgen-ex99_1.htm

EX-99.1 2 rgen-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports Second Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance • Second quarter revenue of $204 million, a year-over-year increase of 12% as reported and 13% organic • GAAP operating income increased 1% year-over-year while adjusted operating income increased 55% • Raising both FY26 organic revenue growth guidance to 10.5%-13.5% and adjusted EPS to $2.03-$2.09 WALTHAM, Mass., July 28, 2026 -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its second quarter of 2026, covering the three-month period ended June 30, 2026. The Company is also providing updated financial guidance for the full year 2026. Olivier Loeillot, President and Chief Executive Officer of Repligen said, “We were very pleased to deliver 13% organic growth in the second quarter, reflecting sequential acceleration and continued market outperformance. This reflects the strength and diversification of our portfolio and …

Open exhibit ↗

Get the free weekly BCS email.